Carmell announces successful closing of merger with axolotl biologix and launch of a new brand identity

Pittsburgh & flagstaff, ariz.--(business wire)--carmell corporation (nasdaq: ctcx) (“carmell”), a regenerative care company today announced the successful closing of the previously announced merger with flagstaff-based axolotl biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and orthopedic indications (“axolotl”). as previously indicated, the initial merger consideration consists of $8 million in cash and $57 million in ctcx comm.
CTCX Ratings Summary
CTCX Quant Ranking